サンプル依頼リスト カート
  • English
  • Korean
表紙：細菌性肺炎の世界市場-2023年～2030年
市場調査レポート
商品コード
1345405

細菌性肺炎の世界市場-2023年～2030年

Global Bacterial Pneumonia Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
細菌性肺炎の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の細菌性肺炎市場は、2022年に27億米ドルに達し、2023-2030年の予測期間にCAGR 8.1％で成長し、2030年には50億米ドルに達すると予測されています。

細菌性肺炎の市場動向は、技術的進歩や調査研究の増加に起因する研究の高まりを示します。細菌性肺炎の治療には、いくつかの抗生物質が発売されています。また、成人や小児における細菌性肺炎の予防のためにワクチンも利用されています。

さらに、承認されたワクチンや薬剤の利用可能性の高まりによる細菌性肺炎の治療の増加、市場における細菌によって引き起こされる肺炎の症例数の増加、研究開発の増加が細菌性肺炎の市場規模を押し上げています。

同市場は、この分野における進歩の高まりの結果、北米地域のワクチン需要が伸びています。Innoviva Inc.、Pfizer Inc.、Merck & Co., Inc.、Aridis Pharmaceuticals Inc.などの主要な競合企業が積極的に市場に参入していることから、市場は今後成長すると思われます。

ダイナミクス

新製品上市数の増加が細菌性肺炎市場の成長を牽引

細菌性肺炎は、臨床試験における安全性と有効性の結果が良好であったことから、新規製品の上市が相次ぎ、大きな成長が見込まれます。例えば、2022年3月14日、ベリティ・ファーマシューティカルズ・インターナショナル社とカンバーランド・ファーマシューティカルズ社は、カンバーランド社のVIBATIV（telavancin）注射剤のプエルトリコでのイントロダクションを発表しました。

両社の合意に基づき、ベリティ社に同剤の上市のゴーサインが出されました。VIBATIVは、インフルエンザやCOVID-19のような病気が原因で発症した病院内肺炎や人工呼吸器関連肺炎の患者の命を救うことができるかもしれません。

FDAが承認し特許を取得した注射用抗感染症薬はVIBATIVと呼ばれます。メチシリン感受性黄色ブドウ球菌（MSSA）やメチシリン耐性黄色ブドウ球菌（MRSA）、その他のグラム陽性菌によって引き起こされる重症感染症の治療を目的としています。VIBATIVは、治療が困難で多剤耐性であるさまざまなグラム陽性菌感染症に対応しています。同市場は、高い調査研究により、予測期間を通じて主導権を握ると予測されています。

主要企業や複数の組織による共同研究の増加が市場成長の機会を創出

長年の研究の結果、多くの大手メーカーや政府/非政府組織が、院内肺炎などのいくつかの疾患を治療する抗生物質として使用するために、いくつかの新規製品の開発や研究のために協力するようになり、細菌性肺炎市場の拡大を促進しています。

例えば、2023年7月10日には、Melinta Therapeutics, LLCとBiomedical Advanced Research and Development Authority（BARDA）との間で、VABOMERE（メロペネムおよびバボルバクタム）とBAXDELA（デラフロキサシン）という、現在FDAが成人用に承認している2種類の抗生物質を小児用に使用するための提携が発表されました。Melinta Therapeutics, LLCは、急性疾患や生命を脅かす疾患に対する新規治療薬を開発する商業段階の企業です。

さらに、メリンタ社とBARDAは、生物学的脅威をもたらす疾患に対する薬剤であるBAXDELAの創製で協力します。BARDAは、この契約の基本期間として2,050万米ドルを提供し、さらに資金調達オプションとして1億2,140万米ドルを追加し、各オプションが行使された場合、合計で最大1億4,190万米ドルの投資となります。このような研究協力は、細菌性肺炎に関する高度な研究を通じて、より良い治療法を提供するのに役立つ可能性があります。

治療に伴う副作用が市場の成長を妨げる

臨床試験中にVABOMEREを投与された患者は、過敏反応を経験したと報告しています。βラクタム系抗菌薬による治療を受けている患者からは、重篤な皮膚反応と同様に、重篤で時には致命的な過敏反応が報告されています。

ワクチンに対して過敏症であったにもかかわらず、別のβラクタム系抗菌薬を服用している人が重篤な過敏症反応を起こした例もあります。バボメールを含むほぼすべての抗菌薬は、中等度の下痢から致命的な大腸炎まで、重症度の幅があるClostridioides difficile関連下痢（CDAD）に関連しています。

CDADは抗菌薬投与後2カ月以上経過してから発症することが知られているため、十分な病歴聴取が必要です。VABOMEREの成分であるメロペネムは、痙攣や中枢神経系を含む他の重篤な反応に関連しています。これらの要素は市場の拡大を制限する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新製品の上市数の増加
      • 細菌性肺炎の増加
    • 抑制要因
      • 治療に伴う副作用
    • 機会
      • 主要企業または複数の組織による共同研究の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 市中肺炎（CAP）
  • 院内肺炎（HAP）
    • 人工呼吸器関連肺炎（VAP）
    • 医療関連肺炎（HCAP）

第8章 投与経路別

  • 経口
  • 皮下
  • その他

第9章 治療法別

  • ワクチン
    • 肺炎球菌結合型ワクチン
    • 肺炎球菌多糖体ワクチン
  • 薬剤
    • フルオロキノロン系抗菌薬
      • シプロフロキサシン
      • デラフロキサシン
      • ジェミフロキサシン
      • レボフロキサシン
    • モノバクタム系抗菌薬
      • アザクタム
      • アストレオナム
    • テトラサイクリン系
      • ドキシサイクリン
      • クロルテトラサイクリン
      • オキシテトラサイクリン
    • マクロライド
      • アジスロマイシン
      • クラリスロマイシン
      • エリスロマイシン
    • カルバペネム系抗生物質
      • ドリペネム
      • エルタペネム
    • 抗生物質
      • リンコマイシン
      • ピルリマイシン
      • クリンダマイシン

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Innoviva Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Melinta Therapeutics LLC
  • Evopoint Biosciences
  • Aridis Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals Inc.
  • Eagle Pharmaceuticals, Inc.
  • Clarametyx Biosciences
  • Basilea Pharmaceutica Ltd

第14章 リストは網羅的ではない

第15章 付録

目次
Product Code: PH6777

Overview

The global Bacterial Pneumonia market reached US$ 2.7 billion in 2022 and is expected to reach US$ 5.0 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2023-2030.

The bacterial pneumonia market trends show rising research owing to the rising technological advancements and research studies. Several antibiotics are being launched for the treatment of bacterial pneumonia. Vaccines are also utilized for prevention of bacterial pneumonia in adults as well as pediatrics.

Furthermore, rising treatment for bacterial pneumonia due to the rising availability of approved vaccines or drugs and increase in the number of pneumonia caused by bacteria cases in the market, and an increase in the research and development is driving up the bacterial pneumonia market size.

The market is experiencing a growth in demand for vaccines from North America areas as a result of the rising advancements in this field. With significant competitors like Innoviva Inc., Pfizer Inc., Merck & Co., Inc., and Aridis Pharmaceuticals Inc. actively operating in the market, the market will grow in upcoming time.

Dynamics

The Growing Number of Novel Product Launches Drive the Growth of the Bacterial Pneumonia Market

Bacterial pneumonia is going to see tremendous growth owing to positive safety and efficacy outcomes in clinical trials leading to novel product launches. For instance, on March 14, 2022, the introduction of Cumberland's VIBATIV (telavancin) injectable in Puerto Rico was announced by the specialized pharmaceutical firms Verity Pharmaceuticals International Ltd. and Cumberland Pharmaceuticals Inc.

Following an agreement between the businesses, Verity was given the go-ahead to launch the medicine for patients in the respective market. In people who have hospital-acquired or ventilator-associated pneumonia brought on by diseases like the flu and COVID-19, VIBATIV may be able to save their lives.

An FDA-approved and patented injectable anti-infective is called VIBATIV. It is intended to treat severe infections brought on by Methicillin-sensitive Staphylococcus aureus (MSSA) or Methicillin-resistant Staphylococcus aureus (MRSA), as well as other Gram-positive bacteria. A variety of Gram-positive bacterial infections, among which are difficult to treat and multidrug resistant, are addressed by VIBATIV. The market is predicted to take the lead throughout the forecast period owing to high research studies.

Rising Collaboration by Key Players or Several Organizations Creates Opportunities for the Growth of the Market

As a result of years of study, a number of major manufacturers or governmental/non-governmental organizations are now collaborating for development or study of several novel products for their usage as antibiotics to treat several diseases such as hospital acquired penumonia, which is promoting the expansion of the bacterial pneumonia market.

For instance, on July 10, 2023, a partnership between Melinta Therapeutics, LLC and the Biomedical Advanced Research and Development Authority (BARDA) has been announced to advance two antibiotics that are currently FDA-approved for adults, VABOMERE (meropenem and vaborbactam) and BAXDELA (delafloxacin), for use in pediatrics. Melinta Therapeutics, LLC is a commercial-stage company that develops novel therapies for acute and life-threatening illnesses.

Additionally, Melinta and BARDA will collaborate on the creation of BAXDELA, a drug against diseases that pose a biothreat. BARDA has provided $20.5 million for the base duration of this contract, plus an additional $121.4 million in funding options, for a total investment of up to $141.9 million if each of the options are exercised. Such research collaborations may help in providing better treatments via high study on bacterial pneumonia.

Side Effects Associated with the Treatments will hamper the growth of the market

Patients who received VABOMERE during the clinical trials reported experiencing hypersensitivity responses. Patients getting treatment with beta-lactam antibacterial medications have reported serious and occasionally deadly hypersensitivity reactions as well as serious skin reactions.

There have been cases where people taking another beta-lactam antibacterial medicine developed significant hypersensitivity reactions despite having a history of being hypersensitive to Vaccines. Nearly all antibacterial medications, including VABOMERE, have been linked to Clostridioides difficile-associated diarrhea (CDAD), which can range in severity from moderate diarrhea to deadly colitis.

Since CDAD has been known to occur more than two months following the administration of antimicrobial Treatments, a thorough medical history is required. Meropenem, an ingredient in VABOMERE, has been linked to seizures and other severe reactions involving the central nervous system. These elements can limit the market's expansion.

Segment Analysis

The global bacterial pneumonia market is segmented based type, treatments and distribution channel.

Owing to High Prevalence, the Community-Acquired Pneumonia (CAP) from Type Segment Accounted for Approximately 68.2% of the Bacterial Pneumonia Market Share

The community-acquired pneumonia (CAP) category from type held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of Bacterial Pneumonia worldwide. One of the most prevalent infectious diseases and a significant contributor to global mortality and morbidity is community-acquired pneumonia (CAP).

Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae are examples of common bacterial infections that cause CAP. According to National Institute of Health, the estimated global incidence of community-acquired pneumonia, which is influenced by geography, the season, and population characteristics, ranges from 1.5 to 14 cases per 1000 person-years.

The most common reason for hospitalization, fatality, and high medical expenses is community-acquired pneumonia. Determining the right level of care is crucial for improving results in addition to early detection and appropriate and prompt treatment because disease presentation can range from a mild illness which can be handled as an outpatient to a serious condition that requires treatment in the intensive care unit.

Geographical Penetration

North America Accounted for Approximately 37.1% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for bacterial pneumonia treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for treatments for bacterial pneumonia.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of bacterial infections, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of bacterial pneumonia market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various treatments and drugs for bacterial pneumonia that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the bacterial pneumonia market include: Innoviva Inc., Pfizer Inc., Merck & Co., Inc., Melinta Therapeutics LLC, Evopoint Biosciences, Aridis Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Eagle Pharmaceuticals, Inc., Clarametyx Biosciences and Basilea Pharmaceutica Ltd among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide bacterial pneumonia market. The growth of the global bacterial pneumonia market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

  • Community-Acquired Pneumonia (CAP)
  • Hospital-Acquired Pneumonia (HAP)
    • Ventilator-associated pneumonia (VAP)
    • Healthcare-associated pneumonia (HCAP)

By Route of Administration

  • Oral
  • Subcutaneous
  • Others

By Treatments

  • Vaccines
    • Pneumococcal Conjugate Vaccines
    • Pneumococcal Polysaccharide Vaccine
  • Drugs
  • Fluoroquinolones
    • Ciprofloxacin
    • Delafloxacin
    • Gemifloxacin
    • Levofloxacin
  • Monobactams
    • Azactam
    • Aztreonam
  • Tetracyclines
    • Doxycycline
    • Chlortetracycline
    • Oxytetracycline
  • Macrolides
    • Azithromycin
    • Clarithromycin
    • Erythromycin
  • Carbapenems
    • Doripenem
    • Ertapenem
  • Antibiotics
    • Lincomycin
    • Pirlimycin
    • Clindamycin

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On July 27, 2023, Merck released encouraging topline findings from two Phase 3 studies assessing V116, the company's experimental 21-valent pneumococcal conjugate Drugs, in those who had never received a Drugs before and those who had. The first pneumococcal conjugate vaccination created especially for adults, if authorized, would be V116. Results from the STRIDE-3 trial showed that in adults who had never received a Drugs, serotype-specific opsonophagocytic activity (OPA) measured 30 days after vaccination revealed significant immune responses in comparison with PCV20 (pneumococcal 20-valent conjugate Drugs).
  • On June 1, 2023, the Phase 3 program, which included the ASSEMBLE (NCT03580044) and REVISIT (NCT03329092) studies evaluating the effectiveness, safety, and acceptability of the newly developed investigational antibiotic aztreonam-avibactam (ATM-AVI) combination in treating severe bacterial infections caused by Gram-negative bacteria, has produced encouraging results, according to Innoviva Inc. Data show that ATM-AVI is safe, efficacious, well-tolerated, and has an identical safety profile to that of aztreonam alone.
  • On May 4, 2021, a generic version of Erythromycin Tablets, the reference listed drug (RLD) by Arbor Pharmaceuticals, 250 mg or 500 mg strength generic Erythromycin tablets have been released by Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. The generic Erythromycin pills from Teva are prescribed to treat a range of bacterial illnesses as well as to stop the onset or recurrence of rheumatic fever in those who are penicillin allergic.

Why Purchase the Report?

  • To visualize the global bacterial pneumonia market segmentation based on type, route of administration, treatments, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of bacterial pneumonia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bacterial pneumonia market report would provide approximately 53 tables, 54 figures and 195 Pages.

DMI Opinion:

The global bacterial pneumonia market is going to see decent growth in upcoming years owing to rising usage of bacterial pneumonia vaccine and novel product launches. Several researches are taking place worldwide for pneumonia vaccine development. Numerous advances are taking place leading to the growth of market such as novel antibiotics. According to DMI the bacterial pneumonia market will see a decent growth with several novel therapies in the market.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Treatments
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Number of Novel Product Launches
      • 4.1.1.2. Rising Prevalence of Bacterial Pneumonia
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with the Treatments
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Collaboration by Key Players or Several Organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Community-Acquired Pneumonia (CAP) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hospital-Acquired Pneumonia (HAP)
    • 7.3.1. Ventilator-associated pneumonia (VAP)
    • 7.3.2. Healthcare-associated pneumonia (HCAP)

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Subcutaneous
  • 8.4. Other

9. By Treatments

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
    • 9.1.2. Market Attractiveness Index, By Treatments
  • 9.2. Vaccines *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Pneumococcal Conjugate Vaccines
    • 9.2.4. Pneumococcal Polysaccharide Vaccine
  • 9.3. Drugs
    • 9.3.1. Fluoroquinolones
      • 9.3.1.1.1. Ciprofloxacin
      • 9.3.1.1.2. Delafloxacin
      • 9.3.1.1.3. Gemifloxacin
      • 9.3.1.1.4. Levofloxacin
    • 9.3.2. Monobactams
      • 9.3.2.1.1. Azactam
      • 9.3.2.1.2. Aztreonam
    • 9.3.3. Tetracyclines
      • 9.3.3.1.1. Doxycycline
      • 9.3.3.1.2. Chlortetracycline
      • 9.3.3.1.3. Oxytetracycline
    • 9.3.4. Macrolides
      • 9.3.4.1.1. Azithromycin
      • 9.3.4.1.2. Clarithromycin
      • 9.3.4.1.3. Erythromycin
    • 9.3.5. Carbapenems
      • 9.3.5.1.1. Doripenem
      • 9.3.5.1.2. Ertapenem
    • 9.3.6. Antibiotics
      • 9.3.6.1.1. Lincomycin
      • 9.3.6.1.2. Pirlimycin
      • 9.3.6.1.3. Clindamycin

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Innoviva Inc. *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Pfizer Inc.
  • 13.3. Merck & Co., Inc.
  • 13.4. Melinta Therapeutics LLC
  • 13.5. Evopoint Biosciences
  • 13.6. Aridis Pharmaceuticals Inc.
  • 13.7. Cumberland Pharmaceuticals Inc.
  • 13.8. Eagle Pharmaceuticals, Inc.
  • 13.9. Clarametyx Biosciences
  • 13.10. Basilea Pharmaceutica Ltd

14. LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us